The Bowel Function Index for Evaluating Constipation in Pain Patients: Definition of a Reference Range for a Non-Constipated Population of Pain Patients

Abstract

Opioid-induced constipation (OIC) is a severe, persisting side-effect of opioid therapy. The Bowel Function Index (BFI^a, numerical analogue scale 0 − 100), calculated as the mean of three variables (ease of defaecation, feeling of incomplete bowel evacuation, and personal judgement of constipation) was developed to evaluate bowel function in opioid-treated patients with pain. This clinician-administered tool allows easy measurement of OIC from the patient's perspective. The purpose of this investigation was to define a reference range reflecting BFI values in non-constipated chronic pain patients who were recruited into a cross-sectional survey and asked for their perceptions of constipation. The BFI scores were assessed and compared with those of patients with confirmed OIC obtained from two previously published trials. Results were analysed and a reference range of BFI values of 0 − 28.8, into which 95% of non-constipated chronic pain patients fell, was defined. This permits discrimination between chronic pain patients with, or without, constipation.

Keywords

Bowel Function Index Opioid-induced bowel dysfunction Chronic pain Constipation Opioids Patient-reported outcomes Oral prolonged-release oxycodone/naloxone combination

References

World Health Organization (WHO): Cancer Pain Relief. Geneva: WHO, 1996 (available at: http://whqlibdoc.who.int/publications/9241544821.pdf).

Ballantyne

: Opioid analgesia: Perspectives on right use and utility. Pain Physician 2007; 10: 479–491.

Pappagallo

: Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182 (5A suppl): 11S–18S.

Panchal

Müller-Schwefe

Wurzelmann

: Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61: 1181–1187.

Leslie

Annunziata

Freedman

: Opioid-induced constipation compromises pain management and impacts patients quality of life. Anaesthesiology 2006; 105: A1490 (abstract).

Kurz

Sessler

: Opioid-induced bowel dysfunction: Pathophysiology and potential new therapies. Drugs 2003; 63: 649–671.

Becker

Galandi

Blum

: Peripherally acting opioid antagonists in the treatment of opiate-related constipation: A systematic review. J Pain Symptom Manage 2007; 34: 547–565.

Reimer

Hopp

Zenz

: Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach. Pharmacology 2009; 83: 10–17.

Yuan

Israel

: Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 2006; 15: 541–552.

10.

Connell

Hilton

Irvine

: Variation of bowel habit in two population samples. Br Med J 1965; 2: 1095–1099.

11.

Longstreth

Thompson

Chey

: Functional bowel disorders. Gastroenterology 2006; 130: 1480–1491.

12.

Frank

Kleinman

Farup

: Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 870–877.

13.

Slappendel

Simpson

Dubois

: Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain. Eur J Pain 2006; 10: 209–217.

14.

Marquis

De La Loge

Dubois

: Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005; 40: 540–551.

15.

Rentz

Müller-Lissner

: Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009; 12: 371–383.

16.

Löwenstein

Leyendecker

Hopp

: Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: A randomised controlled trial. Expert Opin Pharmacother 2009; 10: 531–543.

17.

Meissner

Leyendecker

Mueller-Lissner

: A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009; 13: 56–64.

18.

Nadstawek

Leyendecker

Hopp

: Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract 2008; 62: 1159–1167.

19.

Smith

Hopp

Mundin

: Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 2008; 30: 2051–2068.

20.

Vondrackova

Leyendecker

Meissner

: Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144–1154.

21.

Löwenstein

Leyendecker

Lux

: Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: Results of a prospectively designed pooled analysis of two randomized, double-blind clinical trials. BMC Clin Pharmacol 2010; 10: 12.

22.

Simpson

Leyendecker

Hopp

: Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503–3512.

23.

Wright

Royston

: Calculating reference intervals for laboratory measurements. Stat Methods Med Res 1999; 8: 93–112.

24.

Bell

Panchal

Miaskowski

: The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Med 2009; 10: 35–42.

25.

McMillan

: Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004; 11 (3 suppl): 3–9.

26.

Rentz

van de Jonge

P Hanswijck

Leyendecker

: Observational, nonintervention, multicenter study for validation of the bowel function index for constipation in European countries. Curr Med Res Opin 2011; 27: 35–44.